Google
Trusted Resources: News & Events
Latest announcements and gatherings
100 Years But Only One Drug: Sickle Cell Patients Wait For Help
Last week, 100,000 Americans with sickle cell disease and millions more around the world got encouraging news. Investors gave a vote of confidence, in the form of a $120 million IPO, to Global Blood Therapeutics (NASDAQ: GBT), a four-year-old biotech working on a pill that could become the biggest medical advance ever for the disease.
That pill, which just began its first human trial in January, is a once-a-day medicine that a patient would have to take for life. If approved, the drug would be the only sickle cell treatment to potentially halt the effects of the disease. The lone drug currently on the market for the disease only addresses some of its symptoms.
+myBinderRelated Content
-
Transfusion Medicine, An Issue of Hematology/Oncology Clinics of North AmericaBlood transfusions are an important part...
-
ATS Releases Guidelines for Home Oxygen Therapy in Children With Sickle Cell DiseaseThe American Thoracic Society (ATS) rele...
-
Stable engraftment with haploidentical peripheral blood stem cell transplantation in adult patients with sickle cell...The widespread application of allogeneic...
-
FDA Advisory Committee Recommends Approval of Endari™ from Emmaus Life Sciences for the Treatment of Sickle Cell D...Emmaus Life Sciences Inc. announced toda...
-
Gene-Editing Treatment Shows Promise for Sickle Cell DiseaseScientists are seeing promising early re...
-
Experimental Gene Therapy Reverses Sickle Cell Disease for YearsA study of an investigational gene thera...
-
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy PlatformGlobal biotherapeutics leader CSL Behrin...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.